The detection of these molecular changes has clinical implications, since phlebotomy in VHL‐related erythrocytosis may increase the risk and severity of pulmonary hypertension, and regular follow‐up is necessary to assess the risk of thromboembolic complications, pulmonary hypertension, cardiovascular disease and VHL‐related tumours. This evidence concerns the gene VHL and pulmonary arterial hypertension.